

Attorney Docket No.: **ISPH-0543**
Serial No.: **09/851,871**
Page 2

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of the Claims:

1. (Amended) A method for treating an inflammatory skin disorder in an individual in need thereof, comprising topically applying an antisense compound 8 to 30 nucleobases in length targeted to a nucleic acid molecule encoding a human B7-1 (Genbank Accession No. M27533 MN_005191) or B7-2 (Genbank Accession No. L25259 NM_175862) protein to said individual.
2. (Original) The method of claim 1, wherein said antisense compound is an antisense oligonucleotide.
3. (Original) The method of claim 2, wherein at least one covalent linkage of said antisense compound is a modified covalent linkage.
4. (Original) The method of claim 2, wherein at least one nucleotide of said antisense compound has a modified sugar moiety.
5. (Original) The method of claim 2, wherein at least one nucleotide of said antisense compound has a modified nucleobase.
6. (Original) The method of claim 1, wherein said inflammatory skin disorder is psoriasis.

Attorney Docket No.: **ISPH-0543**
Serial No.: **09/851,871**
Page 3

7. (Original) The method of claim 1, wherein said inflammatory skin disorder is contact dermatitis, atopic dermatitis, seborrheic dermatitis, nummular dermatitis, generalized exfoliative dermatitis or eczema.

8. (Original) The method of claim 1, wherein said human B7 protein is human B7-1 protein.

9. (Original) The method of claim 1, wherein said human B7 protein is human B7-2 protein.

10. (Original) The method of claim 1, wherein antisense compounds targeted to both human B7-1 and human B7-2 proteins are topically applied to said individual.

11. (Original) The method of claim 2, wherein said antisense compound is in a formulation selected from the group consisting of a transdermal patch, ointment, lotion, cream, gel, drop, suppository, spray, liquid and powder.

12. (Original) The method of claim 2 wherein said antisense compound comprises at least one lipophilic moiety which enhances the cellular uptake of said antisense compound.

13.-14. (Cancelled)